Merit Medical Systems (MMSI) said Friday that the US Food and Drug Administration granted premarket approval to the company's Wrapsody cell-impermeable endoprosthesis.
With the approval, the healthcare technology company said it will be able to begin selling the device in the USA in 2025.
The device is designed to improve long-term vessel patency in dialysis patients by addressing complications such as stenosis and thrombosis in arteriovenous fistulas or grafts, critical for maintaining adequate blood flow and patient survival during dialysis, Merit Medical said.
Merit Medical shares rose 2.1% in early trading.
Price: 98.28, Change: +2.01, Percent Change: +2.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.